Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shomron Ben-Horin

Showing results (1-10 of 333) with videos related to

Pageof 34
Sort By:
Gastroenterology & Hepatology|April 29, 2017
Reversal of Immunogenicity in Inflammatory Bowel DiseaseShomron Ben-Horin
Gastroenterology|April 30, 2015
Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?Shomron Ben-Horin
Gut|May 27, 2011
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitisShomron Ben-Horin
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Loss of response to anti-tumor necrosis factors: what is the next step?Shomron Ben-Horin
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Expert Opinion on Biological Therapy|August 13, 2019
CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel diseaseAhmad Albshesh, Shomron Ben-Horin
United European Gastroenterology Journal|July 19, 2019
Biologics' switching: new insights toward establishing practice normsHussein Mahagna, Shomron Ben-Horin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Current Opinion in Pharmacology|August 5, 2008
Neuroimmunology of the gut: physiology, pathology, and pharmacologyShomron Ben-Horin, Yehuda Chowers
Alimentary Pharmacology & Therapeutics|December 15, 2021
Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patientsIdo Veisman, Shomron Ben-Horin
Pageof 34

Showing results (1-10 of 333) with videos related to

Sort By:
Pageof 34
Gastroenterology & Hepatology|April 29, 2017
Reversal of Immunogenicity in Inflammatory Bowel DiseaseShomron Ben-Horin
Gastroenterology|April 30, 2015
Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?Shomron Ben-Horin
Gut|May 27, 2011
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitisShomron Ben-Horin
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Loss of response to anti-tumor necrosis factors: what is the next step?Shomron Ben-Horin
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Expert Opinion on Biological Therapy|August 13, 2019
CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel diseaseAhmad Albshesh, Shomron Ben-Horin
United European Gastroenterology Journal|July 19, 2019
Biologics' switching: new insights toward establishing practice normsHussein Mahagna, Shomron Ben-Horin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Current Opinion in Pharmacology|August 5, 2008
Neuroimmunology of the gut: physiology, pathology, and pharmacologyShomron Ben-Horin, Yehuda Chowers
Alimentary Pharmacology & Therapeutics|December 15, 2021
Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patientsIdo Veisman, Shomron Ben-Horin
Pageof 34